Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. Its lead drug candidate, Rencofilstat, binds and inhibits cyclophilins, a class of isomerase enzymes that regulate protein folding. Preclinical studies of Rencofilstat showed reductions in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, and HDV. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. It was incorporated in 2013 and is headquartered in Morristown, New Jersey.